vs
LAKELAND FINANCIAL CORP（LKFN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是LAKELAND FINANCIAL CORP的1.8倍（$127.1M vs $69.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.7%）
总部位于美国佛罗里达州坦帕的非银行消费金融服务提供商，由伊恩·麦基奇尼于1989年创立，业务网络仅覆盖佛罗里达州，核心服务涵盖支票兑现、账单支付、预付费卡、发薪日贷款、免费汇票、网点ATM服务、电汇、公证、传真及邮政服务，目前运营近240家线下零售网点。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LKFN vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$69.7M
两年增速更快
ZLAB
近两年复合增速
0.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $69.7M | $127.1M |
| 净利润 | $26.5M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 38.0% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | 31.8% | — |
| 每股收益（稀释后） | $1.04 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LKFNZLAB
| Q1 26 | $69.7M | — | ||
| Q4 25 | $69.8M | $127.1M | ||
| Q3 25 | $69.0M | $115.4M | ||
| Q2 25 | $66.4M | $109.1M | ||
| Q1 25 | $63.8M | $105.7M | ||
| Q4 24 | $63.6M | $108.5M | ||
| Q3 24 | $61.2M | $101.8M | ||
| Q2 24 | $68.7M | $100.1M |
净利润LKFNZLAB
| Q1 26 | $26.5M | — | ||
| Q4 25 | $29.9M | — | ||
| Q3 25 | $26.4M | $-36.0M | ||
| Q2 25 | $27.0M | $-40.7M | ||
| Q1 25 | $20.1M | $-48.4M | ||
| Q4 24 | $24.2M | — | ||
| Q3 24 | $23.3M | $-41.7M | ||
| Q2 24 | $22.5M | $-80.3M |
毛利率LKFNZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率LKFNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 52.1% | -54.6% | ||
| Q3 25 | 46.4% | -42.3% | ||
| Q2 25 | 49.6% | -50.3% | ||
| Q1 25 | 38.0% | -53.3% | ||
| Q4 24 | 46.0% | -62.6% | ||
| Q3 24 | 45.3% | -66.6% | ||
| Q2 24 | 39.2% | -76.0% |
净利率LKFNZLAB
| Q1 26 | 38.0% | — | ||
| Q4 25 | 42.8% | — | ||
| Q3 25 | 38.3% | -31.2% | ||
| Q2 25 | 40.6% | -37.3% | ||
| Q1 25 | 31.5% | -45.8% | ||
| Q4 24 | 38.1% | — | ||
| Q3 24 | 38.1% | -40.9% | ||
| Q2 24 | 32.8% | -80.2% |
每股收益（稀释后）LKFNZLAB
| Q1 26 | $1.04 | — | ||
| Q4 25 | $1.16 | $-0.05 | ||
| Q3 25 | $1.03 | $-0.03 | ||
| Q2 25 | $1.04 | $-0.04 | ||
| Q1 25 | $0.78 | $-0.04 | ||
| Q4 24 | $0.94 | $-0.09 | ||
| Q3 24 | $0.91 | $-0.04 | ||
| Q2 24 | $0.87 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $85.6M | $689.6M |
| 总债务越低越好 | $183.6M | — |
| 股东权益账面价值 | $749.0M | $715.5M |
| 总资产 | $7.1B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.25× | — |
8季度趋势，按日历期对齐
现金及短期投资LKFNZLAB
| Q1 26 | $85.6M | — | ||
| Q4 25 | $141.3M | $689.6M | ||
| Q3 25 | $192.8M | $717.2M | ||
| Q2 25 | $310.2M | $732.2M | ||
| Q1 25 | $235.2M | $757.3M | ||
| Q4 24 | $168.2M | $779.7M | ||
| Q3 24 | $160.2M | $616.1M | ||
| Q2 24 | $121.2M | $630.0M |
总债务LKFNZLAB
| Q1 26 | $183.6M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $30.0M | — | ||
| Q2 24 | $55.0M | — |
股东权益LKFNZLAB
| Q1 26 | $749.0M | — | ||
| Q4 25 | $762.4M | $715.5M | ||
| Q3 25 | $747.4M | $759.9M | ||
| Q2 25 | $709.9M | $791.7M | ||
| Q1 25 | $694.4M | $810.8M | ||
| Q4 24 | $683.8M | $840.9M | ||
| Q3 24 | $699.1M | $667.7M | ||
| Q2 24 | $654.5M | $704.2M |
总资产LKFNZLAB
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.0B | $1.2B | ||
| Q3 25 | $6.9B | $1.2B | ||
| Q2 25 | $7.0B | $1.2B | ||
| Q1 25 | $6.9B | $1.2B | ||
| Q4 24 | $6.7B | $1.2B | ||
| Q3 24 | $6.6B | $985.3M | ||
| Q2 24 | $6.6B | $987.4M |
负债/权益比LKFNZLAB
| Q1 26 | 0.25× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.08× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LKFNZLAB
| Q1 26 | — | — | ||
| Q4 25 | $114.9M | $-26.0M | ||
| Q3 25 | $36.1M | $-32.0M | ||
| Q2 25 | $16.2M | $-31.0M | ||
| Q1 25 | $28.9M | $-61.7M | ||
| Q4 24 | $102.5M | $-55.8M | ||
| Q3 24 | $18.0M | $-26.8M | ||
| Q2 24 | $21.0M | $-42.2M |
自由现金流LKFNZLAB
| Q1 26 | — | — | ||
| Q4 25 | $103.8M | $-26.7M | ||
| Q3 25 | $31.1M | $-35.0M | ||
| Q2 25 | $14.1M | $-33.9M | ||
| Q1 25 | $27.1M | $-63.2M | ||
| Q4 24 | $93.9M | $-58.4M | ||
| Q3 24 | $15.3M | $-28.2M | ||
| Q2 24 | $18.6M | $-42.9M |
自由现金流率LKFNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 148.7% | -21.0% | ||
| Q3 25 | 45.0% | -30.4% | ||
| Q2 25 | 21.2% | -31.1% | ||
| Q1 25 | 42.5% | -59.9% | ||
| Q4 24 | 147.6% | -53.8% | ||
| Q3 24 | 25.0% | -27.7% | ||
| Q2 24 | 27.0% | -42.9% |
资本支出强度LKFNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 15.9% | 0.5% | ||
| Q3 25 | 7.3% | 2.6% | ||
| Q2 25 | 3.2% | 2.6% | ||
| Q1 25 | 2.8% | 1.5% | ||
| Q4 24 | 13.6% | 2.4% | ||
| Q3 24 | 4.4% | 1.3% | ||
| Q2 24 | 3.5% | 0.7% |
现金转化率LKFNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 3.84× | — | ||
| Q3 25 | 1.37× | — | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 4.24× | — | ||
| Q3 24 | 0.77× | — | ||
| Q2 24 | 0.93× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LKFN
| Net Interest Income | $56.8M | 81% |
| Noninterest Income | $12.9M | 19% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
